ASXL1 and acute myeloid leukemia: Thus, dominant clonal TET2 mutations—particularly when co-occurring with ASXL1—may delineate a biologically aggressive subgroup that shares key pathophysiologic features with secondary AML despite fulfilling strict diagnostic criteria for de novo disease.